Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Durvalumab with olaparib and paclitaxel for high-risk HER... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
0
Authors
Lajos Pusztai
44 more
Lajos Pusztai
•
Christina Yau
42 more
•
Laura Esserman
Published
June 17, 2021
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Cancer Cell
Topics
Biology
Biochemistry
Medicine
Cancer Oncology
Internal Medicine
Show all topics
DOI
10.1016/j.ccell.2021.05.009
License
publisher-specific-oa
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Cancer Cell
Topics
Biology
Biochemistry
Medicine
Cancer Oncology
Internal Medicine
Show all topics
DOI
10.1016/j.ccell.2021.05.009
License
publisher-specific-oa
